Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Google's Verily Makes Clinical Trials Pitch With Big Pharma Pacts

Executive Summary

Verily has kept a low profile since it was set up in 2015 but deals with Novartis, Otsuka, Pfizer and Sanofi reveal the data management giant's ambitions to become a major player in the lucrative clinical studies space.

You may also be interested in...



Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate

Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.

How Novartis Is Making SENSE Of Clinical Data In Digital Age

The Swiss major has been showcasing its Nerve Live data analytics platform, where staff stationed at its SENSE operations center in Basel can monitor 500 or so clinical studies to predict - and stop - potential delays.

Novartis In Line For Ofatumumab MS Approval In June

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel